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Background. Recent artemisinin-combination therapy failures in Cambodia prompted a search for alternatives. Atovaquone‐
proguanil (AP), a safe, effective treatment for multidrug-resistant Plasmodium falciparum (P.f.), previously demonstrated additive 
effects in combination with artesunate (AS).
Methods. Patients with P.f. or mixed-species infection (n = 205) in Anlong Veng (AV; n = 157) and Kratie (KT; n = 48), Cambodia, 
were randomized open-label 1:1 to a fixed‐dose 3-day AP regimen +/-3 days of co‐administered artesunate (ASAP). Single low-dose 
primaquine (PQ, 15 mg) was given on day 1 to prevent gametocyte-mediated transmission.
Results. Polymerase chain reaction–adjusted adequate clinical and parasitological response at 42 days was 90% for AP (95% 
confidence interval [CI], 82%–95%) and 92% for ASAP (95% CI, 83%–96%; P = .73). The median parasite clearance time was 72 
hours for ASAP in AV vs 56 hours in KT (P < .001) and was no different than AP alone. At 1 week postprimaquine, 7% of the ASAP 
group carried microscopic gametocytes vs 29% for AP alone (P = .0001). Nearly all P.f. isolates had C580Y K13 propeller artemisinin 
resistance mutations (AV 99%; KT 88%). Only 1 of 14 treatment failures carried the cytochrome bc1 (Pfcytb) atovaquone resistance 
mutation, which was not present at baseline. P.f. isolates remained atovaquone sensitive in vitro but cycloguanil resistant, with a triple 
P.f. dihydrofolate reductase mutation.
Conclusions. Atovaquone-proguanil remained marginally effective in Cambodia (≥90%) with minimal Pfcytb mutations
observed. Treatment failures in the presence of ex vivo atovaquone sensitivity and adequate plasma levels may be attributable to 
cycloguanil and/or artemisinin resistance. Artesunate co-administration provided little additional blood-stage efficacy but reduced 
post-treatment gametocyte carriage in combination with AP beyond single low-dose primaquine.
Keywords. atovaquone-proguanil; artesunate; drug resistance; malaria; primaquine.
Treatment failures of multiple Plasmodium  falciparum drugs 
have accelerated over the past decade in Cambodia. Most 
recently, substantial rates of clinical dihydroartemisinin-
piperaquine combination therapy failures emerged within 
just 3  years of introduction [1], with confirmed resistance to 
both components [2]. In response, health authorities issued 
guidelines reinstating artesunate-mefloquine combinations as 
firstline agents in affected areas [3]. These were based on ex vivo 
surveillance data indicating inverse resistance patterns between 
piperaquine and mefloquine [4, 5] attributed to Pfmdr1 muta-
tions [6]. This was intended as a stop-gap public health measure 
pending more effective therapies.
Unfortunately, few viable alternatives currently exist, 
prompting calls for more intensive nonpharmacologic ap-
proaches including universal directly observed inpatient treat-
ment [7] and military mobilization [8]. Atovaquone-proguanil 
(AP), a fixed-dose combination that synergistically uncouples 
parasite mitochondria, remains one of the few remaining al-
ternative therapies, with limited use to date as part of a World 
Health Organization (WHO) containment program in Pailin 
province [9] and more recently as a second-line therapy in 
Thailand. Preserved ex vivo efficacy was confirmed in areas of 
recent dihydroartemisinin-piperaquine failure [10]. AP was 
primarily developed as a well-tolerated daily “causal” liver-stage 
prophylaxis drug, but is also effective against multidrug-resistant 
(MDR) malaria [11]. The primary disadvantage of treating P.f. 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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malaria with AP is rapid in-host selection of cytochrome-bc1 
parasite mutations conferring clinical resistance, though resist-
ance without bc1 mutations has also been described [12].
A prior study in Thailand indicated that the combination 
of artesunate with atovaquone-proguanil (ASAP)  (Atlantic 
Laboratories Corp., Ltd., Bangkok, Thailand) is more effec-
tive than AP alone while also reducing subsequent gametocyte 
carriage [13]. In addition to added efficacy, it is possible that 
the combination may delay or prevent further development 
of resistance to the individual agents, given varying mechan-
isms of action. We tested the efficacy of AP with and without 
AS and evaluated the effects of single low-dose primaquine 
(15  mg)  (The Government Pharmaceutical Organization 
(GPO), Bangkok, Thailand) paired with the 2 combinations on 
gametocyte carriage post-treatment.
METHODS
Study Design and Participants
Cambodian volunteers with uncomplicated P.f. or mixed 
P. falciparum/P. vivax malaria aged 18–65 years were enrolled
in a 2-arm open label treatment trial at Anlong Veng Referral
Hospital, Oddar Meanchey Province, and Kratie Provincial
Referral Hospital. Patients with 100–200  000 parasites/μL of
blood were included, whereas patients with severe malaria, al-
lergy, contraindication to study drugs, use of antimalarials in the 
previous 7 days (or atovaquone-proguanil in the previous 30),
and pregnant or lactating women were excluded. Participants
provided written informed consent in Khmer. The study pro-
tocol was approved by US and Cambodian regulatory author-
ities as study WR2115 (ClinicalTrials.gov NCT02297477).
Procedures
Patients were treated in-hospital under directly observed 
therapy. Volunteers were randomly assigned to 3  days of 
atovaquone-proguanil (AP; 1000 mg/400 mg) with or without 
200  mg of artesunate (ASAP) daily with 1:1 allocation using 
time-blocked randomization with a block size of 4. Volunteers 
selected treatment assignment codes from a collection of sealed 
envelopes to mask allocation. Based on published international 
and local guidance by the WHO at the time, all volunteers re-
ceived 15  mg of primaquine on day 1, regardless of G6PD 
status. Microscopists were blinded to each other’s readings and 
to study drug regimen.
All investigational products met quality standards for 
weight and content uniformity by UPLC-MS analysis before 
the study [14]. Volunteer glucose-6-phosphate-dehydrogenase 
(G6PD) activity was evaluated by a fluorescence spot test (R&D 
Diagnostics Ltd., Greece).
Vital signs were taken at 0, 4, and 8 hours after the first dose, 
then every 8 hours until discharge. Giemsa-stained thick and thin 
malaria smears [15] were performed at 4 and 8 hours after first 
study drug dose, then every 8 hours until 2 consecutive negative 
smears. Gametocytemia was evaluated per 2000 white blood 
cell count (WBC) on thin smear, whereas asexual-stage parasit-
emia was per 500 WBC [16]. Real-time polymerase chain reac-
tion (PCR) detection of malaria was performed at 0, 24, 48, and 
72 hours, then weekly and at recurrence [17]. Atovaquone levels 
were collected at 0, 4, 24, 48, and 72 hours, weeks 1 and 2, and 
recurrence. An ultraperformance liquid chromatography (UPLC) 
coupled with tandem mass spectrometry (MS/MS) method in 
human plasma with carboxymefloquine as an internal standard 
was developed, optimized, and validated based on US Food and 
Drug Administration guidance. Plasma atovaquone concen-
tration was measured using a Waters Acquity UPLC BEH C18, 
2.1×50  mm, 1.8-µm column with a gradient mobile phase of 
5 mM of ammonium acetate in water (pH 7.0) and 5 mM of am-
monium acetate in acetonitrile at a flow rate of 0.4 mL/min over 
5 minutes. Plasma samples were extracted by acetonitrile protein 
precipitation with known concentrations of carboxymefloquine. 
Clear supernatants were transferred to UPLC vials after vortexing 
and centrifugation for 10 minutes. Selective mass/charge (m/z) 
transitions were monitored for atovaquone (365.04 to 337.02) and 
carboxymefloquine (307.94 to 223.93).
Volunteers were monitored throughout the study for adverse 
events using Common Terminology Criteria for Adverse Events 
[18], including performance of complete blood count and renal 
and liver function tests at 0, 48, and 72 hours. After discharge, 
outpatient clinical follow-up continued for 42 days, with weekly 
malaria smears. Females had urine pregnancy tests at baseline, 
recurrence, and weeks 2, 4, and 6. Recurrent malaria was treated 
following current national treatment guidelines.
In cases of malaria recurrence, recrudescence was determined 
by P.f. msp1, msp2, and glurp genotyping [19]. Molecular markers 
of resistance were assessed at baseline and recurrence, including 
the K13 propeller marker for artemisinins [1], the cytochrome bc1 
atovaquone mutation [10], and dihydrofolate reductase (DHFR) mu-
tations associated with cycloguanil resistance, an active metabolite 
of proguanil [20]. Sequencing for AS-resistant Pf Kelch 13 variants 
covered the entire pfk13 propeller domain, including previously de-
scribed mutations at R561H, N537I, P553L, G449A, and C580Y. In 
these Cambodian isolates, Pf kelch mutation was only found at posi-
tion C580Y. Additionally, the entire mitochondrial cytochrome b gene 
was sequenced by amplifying a 2.7-kb mtDNA fragment using the 
Sanger method with 8 different sequencing primers (Supplementary 
Table 1). Immediate ex vivo drug susceptibility of fresh P.f. isolates 
to commonly used antimalarials was measured as 50% inhibitory 
concentration (IC50) [1] based on histidine-rich protein 2 (HRP-2) 
enzyme-linked immunosorbent assay (ELISA) [10, 21].
Outcomes
The primary outcome was PCR-adjusted adequate clinical and 
parasitological response (ACPR), defined as absence of clin-
ical or parasitological malaria recurrence within 42  days of 
follow-up.
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Statistical Analysis
Prior efficacy point estimates from a large (n = 1596) compara-
tive study conducted in Thailand a decade earlier [13] were 97% 
for AP and 99% for ASAP. Sample size of 100 in each treatment 
arm was calculated to determine 95% confidence intervals for 
each treatment arm independently around a 90% 42-day per-
protocol efficacy for AP and 95% for ASAP. These were con-
sidered to be acceptable thresholds to support ongoing use as 
tertiary regimens in the national treatment program. Data were 
double-entered into Microsoft Access 2007, with random 20% 
reverification by the clinical study monitor, and analyzed using 
STATA, version 15.0 (Stata Corp, College Station, TX), and 
GraphPad Prism, version 6.07. All patients receiving at least 1 
dose of study drug were included in the intention-to-treat anal-
ysis, whereas per-protocol analysis excluded all withdrawn or 
censored volunteers.
Cumulative risk of treatment failure was assessed with 
Kaplan-Meier survival over 42 days using log-rank comparison 
tests. Cox proportional hazards models were used to assess clin-
ical and molecular covariates and recrudescence. Comparisons 
of categorical variables were made with the Fisher exact test, 
whereas continuous variables were compared with the Student 
t test or Wilcoxon rank-sum test (for non–normally distrib-




Of 221 patients screened with acute P.f. or mixed malaria 
infection, 205 (93%) were enrolled and randomized, with 
95% completing 42-day follow-up (Figure 1). One hundred 
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Figure 1. CONSORT flow diagram. Abbreviations: AP, atovaquone-proguanil; ASAP, artesunate-atovaquone-proguanil; AV, Anlong Veng; FU, follow-up; KT, Kratie; PQ, 
primaquine.
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fifty-seven volunteers were enrolled in northern Cambodia 
(Anlong Veng) and 48 in eastern Cambodia (Kratie), mostly 
symptomatic adult males. Patient baseline characteristics were 
similar between treatment arms and study sites (Table 1). Less 
than 8% had preexisting plasma antimalarial activity detected 
at baseline (Table 2).
Safety
AP combined with AS was well tolerated, with only 2 serious ad-
verse events. One ASAP volunteer had asymptomatic obstructive 
jaundice, with elevated bilirubin, alkaline phosphatase, and as-
partate aminotransferase all >4× upper limit of normal by day 7 
and normalizing by week 2 with normal alanine aminotransferase 
throughout. The volunteer suffered no permanent injury, and al-
though a relationship to the study drug was unexpected, it could 
not be definitively ruled out. One AP volunteer presented with 
gingival bleeding 1 month after treatment and was diagnosed with 
idiopathic thrombocytopenic purpura (ITP), which was assessed 
as unlikely to be related to treatment due to normal blood counts 1 
week post-treatment and delayed symptom presentation.
Clinical Outcomes
PCR-adjusted ACPR against blood-stage malaria infection was sim-
ilar for the 2 regimens at 42 days: 90% for AP (95% confidence in-
terval [CI], 82%–95%) vs 92% for ASAP (95% CI, 83%–96%; P = .617 
by Kaplan-Meier analysis) (Table 2, Figure 2A–C). There were 17 
P.f. malaria recurrences by microscopy, nearly all occurring at the 
AV site (16/17), with 14 PCR-confirmed recrudescences. Thus, al-
though 28-day per-protocol efficacy was at or near 100% at both sites, 
42-day efficacy of both regimens was lower at the AV site (Table 2). 
Treatment outcomes did not differ by baseline parasitemia. Twenty-
five percent of volunteers were excluded from per-protocol analysis 
during follow-up for receiving blood-stage P. vivax treatment.
Parasite Clearance
The median parasite clearance time (PCT) in AV was 72 hours for 
both treatment arms, but was shorter in KT (ASAP 56 hours vs AP 
68 hours; P < .001) (Figure 3A, Table 2). At day 3 post-treatment, 
42% at the AV site remained microscopy-positive compared with 
10% at the KT site (Table 2). However, when measuring parasite 
clearance half-lives (PCT1/2), there were not significant differences 
between sites or intervention arms (Figure 3B).
The majority of treatment failures (12/14) occurred in pa-
tients infected with artemisinin-resistant phenotype parasites 
with PCT >72 hours and PCT1/2 >5 hours (Table 2, Figure 3). 
Despite faster parasite clearance and fewer treatment failures in 
Kratie, nearly all isolates at both sites carried the C580Y K13 
mutation (AV 99% [168/169] vs KT 90% [38/43]) (Figure 3), 
with the remaining isolates having K13 wild-type. All treatment 
failures were C580Y positive, with C580Y parasites cleared 
more slowly than non-C580Y parasites (median PCT1/2, 5.3 in 
C580Y vs 3.4 hours in non-C580Y infections; P = .003).
Parasite Drug Sensitivity
Fresh patient P.f. isolates retained comparable resistance pat-
terns to recent studies at the Anlong Veng site by HRP2 ELISA 
(Figure 4A) [4]. Notably, isolates retained ex vivo atovaquone 
sensitivity at both sites, with geometric mean pretreatment IC50 
of 4.8 nM (95% CI, 3.8–6.0) in AV and 3.5 nM (95% CI, 2.4–5.0) 
in KT (P = .02). ATQ IC50 was evaluable in 5/14 recrudescent 
samples (36%), with a geometric mean IC50 similar to base-
line (4.2 nM; P = .51). All isolate IC50 were far below that of the 
ATQ-resistant C2B clone (11 368 nM) (Figure 4B) [22]. Sanger 
sequencing did not detect a mutation at cytb Y268 associated 
with ATQ resistance in any baseline isolates. Only 1 volunteer 
(ASAP-90) harbored the Y268C mutation at recrudescence 
(1/14), though IC50 was unevaluable. Sequencing across the en-
tire mitochondrial cytochrome b gene was successful in 14 re-
crudescent isolates, but no previously reported [23–25] or new 
single nucleotide polymorphisms (SNPs) were found.
Parasites displayed high-level cycloguanil (CYC) resistance 
(geometric mean pretreatment IC50, 2204  nM), though only 
29% of isolates were successfully evaluated ex vivo (Figure 4B). 
No cycloguanil-specific dihydrofolate-reductase (DHFR) mu-
tations (S108T and A16V) were detected in any of the tested 
isolates. All 14 recrudescent samples had 4 parasite DHFR gene 
SNPs (S108N, N51II, C59R, and I164L) associated with pyri-
methamine resistance and were thought to confer cycloguanil 
cross-resistance [26, 27]. A  randomly sampled subset of 46 
baseline AV samples were also quadruple pyrimethamine mu-
tants, consistent with fixation of this DHFR genotype.
Gametocyte Carriage After Treatment
At screening, 22% of volunteers treated with AP had gametocytemia 
by microscopy vs 26% for ASAP (n.s.) (Figure 5A). ASAP-treated 
volunteers had faster gametocyte decline than AP, reaching statis-
tical significance by day 3 (P = .0009) and remaining significantly 
lower in the ASAP arm through week 2, despite universal base-
line 15-mg primaquine treatment (Figure 5). Median gameto-
cyte densities normalized for baseline values revealed more rapid 
clearance for the ASAP group (Figure 5B and C).
Pharmacology
Mean atovaquone levels were not significantly different between 
treatment groups (Figure 6A) or treatment outcomes (Figure 
6B). Mean atovaquone levels on day 7 in those with ACPR were 
not different than in those who recrudesced (Figure 6C).
DISCUSSION
Implications for Implementation of Rescue Therapies in Areas of Severe 
Multidrug Resistance
Combining a 3-day course of AP with AS in a large, rigorous 
study was shown in 2004 to improve efficacy against MDR P.f. to 
near 100% in Thailand [13]. A decade later in Cambodia, both 
regimens approached 100% 28-day PCR-corrected efficacy, but 
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Table 1. Baseline Characteristics of Study Subjects
Baseline Characteristics
Parameter ASAP AP Sig. Anlong Veng Kratie Sig. Total
Total, No. 102 103 157 48 205
Male sex, No. (%) 99 (97.1) 100 (97.1) 0.990 152 (96.8) 47 (97.9) 0.692 199 (97.1)
Age, mean (IQR), y 31.2 (16) 29.4 (15) 0.180 30.1 (14) 30.8 (16) 0.652 30.3 (14)
Age, median (IQR), y 28.0 (16) 28.0 (15) 0.275 28 (14) 28 (16) 0.951 28 (14)
Khmer ethnicity, No. (%) 102 (100) 103 (100) - 157 (100) 48 (100) - 205 (100)
Occupation, No. (%)
 Farmer 94 (92.2) 97 (94.2) 0.567 145 (92.4) 46 (95.8) 0.403 191 (93.2)
 Military 7 (6.9) 5 (4.9) 0.540 12 (7.6) 0 (0.0) 0.048 12 (5.8)
 Other 1 (1.0) 1 (1.0) 0.994 0 (0.0) 2 (4.2) 0.010 2 (1.0)
Weight, mean (SD), kg 56.0 (7.1) 55.1 (6.5) 0.337 55.6 (6.7) 55.4 (7.0) 0.862 55.6 (6.8)
Body mass index, No. (%)
Underweight <18.5 kg/m2 9 (8.8) 13 (12.6) 0.380 14 (8.9) 8 (16.7) 0.129 22 (10.7)
Normal 18.5–24.9 kg/m2 88 (86.3) 87 (84.5) 0.714 138 (87.9) 37 (77.1) 0.064 175 (85.4)
Overweight 25–29.9 kg/m2 5 (4.9) 3 (2.9) 0.462 5 (3.2) 3 (6.3) 0.337 8 (3.9)
Symptoms, No. (%)
 Fever 101 (99.0) 103 (100) 0.314 156 (99.4) 48 (100) 0.579 204 (99.5)
 Headache 99 (97.1) 103 (100) 0.080 155 (98.7) 47 (97.9) 0.683 202 (98.5)
Muscle aches 62 (60.8) 61 (59.2) 0.820 103 (65.6) 20 (41.7) 0.003 123 (60.0)
 Chills 85 (83.3) 85 (82.5) 0.878 124 (79.0) 46 (95.8) 0.007 170 (82.9)
Abdominal pain 26 (25.5) 30 (29.1) 0.559 51 (32.5) 5 (10.4) 0.003 56 (27.3)
 Dizziness 18 (17.6) 24 (23.3) 0.316 27 (17.2) 15 (31.3) 0.035 42 (20.5)
 Fatigue 20 (19.6) 18 (17.5) 0.694 26 (16.6) 12 (25.0) 0.188 38 (18.5)
 Nausea 11 (10.8) 11 (10.7) 0.981 12 (7.6) 10 (20.8) 0.010 22 (10.7)
 Vomit 1 (1.0) 2 (1.9) 0.567 2 (1.3) 1 (2.1) 0.683 3 (1.5)
 Diarrhea 1 (1.0) 1 (1.0) 0.994 2 (1.3) 0 (0.0) 0.432 2 (1.0)
 Anorexia 1 (1.0) 0 (0.0) 0.314 0 (0.0) 1 (2.1) 0.070 1 (1.0)
Temperature, mean (SD), ℃ 37.9 (0.8) 37.7 (0.9) 0.124 37.8 (0.8) 38.0 (1.0) 0.138 37.8 (0.8)
Duration of fever, median (IQR), d 2 (1) 2 (1) 0.542 2 (2) 3 (1) 0.000 2 (1)
History of previous malaria episode, No. (%) 64 (62.7) 71 (68.9) 0.350 114 (72.6) 21 (43.8) 0.000 135 (65.9)
History of malaria medication, No. (%)
≥1–<2 wk 1 (1.0) 0 (0.0) 0.314 0 (0.0) 1 (2.1) 0.070 1 (0.5)
≥2–<4 wk 2 (2.0) 10 (9.7) 0.018 12 (7.6) 0 (0.0) 0.048 12 (5.9)
≥1–<3 mo 33 (32.4) 42 (40.8) 0.211 59 (37.6) 16 (33.3) 0.593 75 (36.6)
≥3–<6 mo 12 (11.8) 12 (11.7) 0.980 23 (14.6) 1 (2.1) 0.018 24 (11.7)
≥6–<12 mo 16 (15.7) 7 (6.8) 0.044 20 (12.7) 3 (6.3) 0.213 23 (11.2)
Hepatomegaly, No. (%) 0 (0.0) 1 (1.0) 0.318 1 (0.6) 0 (0.0) 0.579 1 (0.5)
Splenomegaly, No. (%) 1 (1.0) 1 (1.0) 0.994 1 (0.6) 1 (2.1) 0.372 2 (1.0)




0.259 7491.8 (841, 76661)8494.9 (310, 
88519)
0.168 7715.5 (832, 
76661)
Parasite density group, No. (%)
 <1000/µL 8 (7.8) 9 (8.7) 0.816 12 (7.6) 5 (10.4) 0.542 17 (8.3)
≥1000 and ≤10 000/µL 49 (48.0) 53 (51.5) 0.625 81 (51.6) 21 (43.8) 0.342 102 (49.8)
>10 000 and ≤100 000/µL 45 (44.1) 37 (35.9) 0.231 61 (38.9) 21 (43.8) 0.545 82 (40.0)
>100 000/µL 0 (0.0) 4 (3.9) 0.044 3 (1.9) 1 (2.1) 0.940 4 (1.9)
Presence of Pf gametocytes, No. (%) 24 (23.5) 18 (17.5) 0.283 33 (21.0) 9 (18.8) 0.733 42 (20.5)
Creatinine clearance, mean (SD) 94.1 (19.8) 94.8 (18.9) 0.785 96.9 (18.7) 86.5 (19.4) 0.001 94.5 (19.3)
White cell count, median (IQR), ×103/µL 6.1 (3.4) 6.5 (2.6) 0.368 6.5 (2.8) 6.1 (3.1) 0.084 6.4 (2.9)
Red cell count, median (IQR), ×106/µL 4.7 (0.9) 4.9 (0.9) 0.043 4.8 (0.8) 5.1 (0.9) 0.004 4.8 (0.8)
Hemoglobin, mean (SD), g/dL 12.7 (1.6) 13.0 (1.7) 0.203 12.8 (1.6) 13.3 (1.7) 0.031 12.9 (1.6)
Hematocrit, mean (SD) 37.8 (4.6) 38.7 (4.8) 0.161 37.4 (4.4) 41.0 (4.7) 0.000 38.2 (4.7)
Platelet count, median (IQR), ×103/µL 139 (62) 143 (70) 0.929 147 (65) 128 (62) 0.004 141 (66)
Absolute neutrophil count, median (IQR), 
×103/µL
4.0 (2.8) 4.2 (2.9) 0.556 4.3 (2.9) 3.6 (2.8) 0.154 4.2 (2.8)
G6PD deficiency, No. (%) 12 (11.8) 17 (16.5) 0.330 25 (15.9) 4 (8.3) 0.187 29 (14.1)
Abbreviations: AP, atovaquone-proguanil; ASAP, artesunate-atovaquone-proguanil; IQR, interquartile range. Bolded text refers to statistically significant results.
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Figure 2. Clinical efficacy. Kaplan-Meier survival analysis of artesunate-atovaquone-proguanil (ASAP) efficacy over 42 days vs atovaquone-proguanil (AP) alone at 2 sites 
in Cambodia based on number of volunteers remaining malaria free at each interval (inset). A, Overall (log-rank P value for difference = .617). B, Anlong Veng site. C, Kratie 
site. There were no statistical differences in outcomes for AP (P = .663) or ASAP (P = .317) by location.
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hovered at 90% by day 42. Findings here are consistent with pre-
vious observations that AP treatment failures before day 28 are 
rare [28] and thought to be due to poor drug absorption. AP 
was administered with food under the study protocol to ensure 
sufficient absorption. Low dropout rates (<5%) lend confidence 
to the efficacy findings.
Given recent failures of firstline treatment drugs [1, 7], it was 
hoped that the ASAP combination might preserve drug efficacy. 
There has been a measurable shift in antimalarial resistance pat-
terns in the past 17 years since van Vugt et al. published their 
original report in 2002 [13]. At that time, artemisinin resistance 
had yet to be clearly defined. Atovaquone-proguanil had not yet 
been deployed in Western Cambodia to mitigate emerging re-
sistance, and it was 12 years before clinical dihyrdroartemisinin-
piperaquine failures were reported in Cambodia. Recent claims 
of malaria “superbugs” in Cambodia and elsewhere [29] under-
score the urgent need for alternative regimens using therapies 
in hand, as was attempted in the present trial. We sought to de-
termine whether AP remains a deployable option and whether 
AS might help to boost its efficacy. Given the resultant 90%–
92% efficacy estimate here compared with 97%–99% previously 
observed in neighboring Thailand, there is reason to believe this 
approach would be suboptimal in Cambodia. High rates of mi-
croscopic gametocytemia, even in combination with low-dose 
primaquine, also raise concerns regarding the utility of ASAP 
as a firstline regimen in an elimination campaign.
Atovaquone Resistance
Despite a nearly 10% treatment failure rate, measurable 































































Figure 3. Parasite clearance times (A) and parasite clearance half-life (B) in Northern (Anlong Veng) and Eastern (Kratie) Cambodia by treatment regimen. All patients with 
treatment failure assigned to ASAP had a parasite clearance half-life (PCT1/2) >5 hours. Red dots represent parasite recrudescence based on genotyping with msp1, msp2, 
and glurp polymorphisms. Clear dots represent parasites with the K13 propeller C580Y mutation, green dots represent K13 wild-type parasites, and blue dots represent K13 
propeller status unknown. The orange error bars represent medians and interquartile ranges for the variables presented. Comparison of parasite clearance time by t test with 
Mann-Whitney test revealed significantly faster parasite clearance time for the ASAP treatment vs AP in Eastern Cambodia only (P = .04). There were no significant differ-
ences in parasite clearance half-life overall. The median PCT1/2 was significantly higher at 5.34 nM for parasites with the K13 propeller C580Y mutation vs 3.42 for parasites 
without C580Y (P = .0032).
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drug levels well above baseline parasite IC50 and absent cyto-
chrome bc1 mutations in all but 1 volunteer detected at week 
5. Interestingly, this single mutation was not detected at base-
line, suggesting that it may have arisen de novo or existed as a
minority variant that was selected through treatment. De novo
mutations refer to cytb Y268 found at recrudescence, but not
at baseline, before treatment. Despite rare de novo mutations,
AP resistance appears to be an all-or-none rather than gradual
phenomenon [30]. In prior studies, most clinical failures attrib-
utable to cytb mutations occurred beyond 28  days. However,
only 1 failure here among 14 was potentially attributable to cytb 
mutation. This was unexpected and argues against atovaquone 
resistance as the cause of treatment failures. As genotyping 
was performed here, based on PCR amplification and Sanger 
sequencing (capturing the majority genotype), this does not 
preclude that cytb Y268 mutations might have been present 
as minority variants at baseline. Preserved ex vivo atovaquone 
sensitivity was found among isolates from a 2013 clinical 
study at the AV site despite >50% clinical dihydroartemisinin-
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Figure 4. Immediate ex vivo Plasmodium falciparum (P.f.) parasite resistance. A, Overall ex vivo P.f. parasite sensitivity to commonly used antimalarial drugs in 2014 from 
field surveillance stations in Cambodia. Red bars represent geometric mean values, whereas green dashed lines represent values for the W2 Indochina P.f. clone. B. Ex vivo 
parasite sensitivity by histidine-rich protein 2 enzyme-linked immunosorbent assay to atovaquone and cycloguanil for evaluable isolates on the day of study screening before 
treatment (D0) and day of recrudescence (DR). Baseline assays were interpretable for only 93 of 202 isolates for atovaquone (46%) and 46 of 160 (29%) for cycloguanil. Clear 
dots represent parasites with the cytb atovaquone resistance gene wild-type, and blue dots represent K13 propeller status unknown. Red bars in each column represent 
geometric mean 50% inhibitory concentration (IC50) values, whereas dashed green lines represent mean values for the chloroquine-resistant W2 Indochina clone run simulta-
neously for each assay. Dashed blue lines represent geometric mean values for the atovaquone-resistant C2B clone. Dashed orange lines represent geometric mean values 
for the chloroquine-sensitive D6 clone. Geometric mean atovaquone IC50 for parasites with the C580Y mutation was significantly higher (4.57 nM; n = 94) than for non-C580Y 
parasites (1.29 nM; n = 4; P = .001).
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Atovaquone-proguanil was used in WHO-sponsored malaria 
containment efforts along the Thai border beginning in 2006 
[9], making the lack of apparent atovaquone resistance sur-
prising. This could be due to apparent loss of parasite fitness in 
the presence of cytb mutations, with parasites developing cytb 
mutations being less likely to persist in the population [31].
Short-Acting Agent Resistance
Insufficient short-acting blood-stage agent activity may have 
contributed to reduced clinical efficacy. In vitro cycloguanil 
IC50 were elevated in the presence of PfDHFR mutations, 
which were previously associated with pyrimethamine re-
sistance and thought to be associated with cycloguanil cross-
resistance [28]. This suggests, though it does not confirm, that 
cycloguanil resistance may have played a role in the clinical 
failures seen here. Although parasites assayed displayed high 
levels of cycloguanil resistance, this finding is tempered by the 
fact that less than one-third of isolates yielded interpretable ex 
vivo cycloquanil sensitivity results. The lack of cycloguanil-
specific dihydrofolate-reductase (DHFR) mutations (S108T 
and A16V) in any of the isolates tested further calls poten-
tial resistance into question. The strongest evidence appears 
to be the presence of 4 parasite DHFR gene SNPs (S108N, 
N51II, C59R, and I164L) in all of the 14 recrudescent samples. 
Although associated with pyrimethamine resistance, prior 
work has indicated that they may confer cycloguanil cross-
resistance [26, 27]. These quadruple pyrimethamine mutants 
were found to be at fixation for this DHFR genotype. This 
suggests high-level DHFR resistance, likely due to persistant 
resistance genotypes from parasites exposed to antimalarials 
and other drugs operating through the DHFR mechanism. 
The use of trimethoprim-sulfamethoxazole and other DHFR 
inihibitors as antibiotics is common in the region and has led 
to high levels of bacterial resistance [32].
Unlike the prior study in Thailand [13], there was no added 
benefit of AS on blood-stage efficacy or PCT1/2. It was previ-
ously suggested that AS should be added to AP well before 
AP resistance develops, but in the present study longstanding 
AS resistance may have rendered this issue moot. The C580Y 
K13 artemisinin-resistance mutation approached fixation, sug-
gesting contributions of both cycloguanil and artesunate re-
sistance (ART-R) to declining efficacy. The majority of clinical 
failures for both regimens occurred at the Along Veng site, where 
longstanding ART-R has contributed to rapidly developing arte-
misinin combination therapy (ACT) failures [1, 33]. AP had not 
been used, nor has significant ART-R been previously reported, 
at the Kratie site. Blood-stage ASAP efficacy was well preserved 
despite high rates of K13 C580Y in Kratie (>85%), supporting 
previous evidence that additional mutations may be needed to 
confer clinically apparent ART-R [34]. Unfortunately, there is 
only limited evidence here that artesunate and/or cycloguanil 
resistance genotypes may have contributed to the modest de-
cline in efficacy. Study design precludes distinguishing the rela-
tive contributions of each.
ASAP (N = 21)
AP (N = 19)
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Figure 5. Gametocyte carriage by light microscopy. A, Number and percentage of subjects found to have Plasmodium falciparum gametocytes by light microscopy from 
each treatment arm during 6 weeks of follow-up. B and C, Median parasite gametocyte densities over the first 2 weeks of follow-up for those subjects who were originally 
gametocytemic, normalized to baseline values on D0 (100%).
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Implications for the Addition of Low-Dose Primaquine to AP-Containing 
Regimens
To date, primaquine has been the only clinically available drug 
shown to effectively kill mature P.f. gametocytes, preventing on-
going transmission [35]. Current WHO guidelines for treatment 
of P.f. malaria recommend single low-dose primaquine with 
blood-stage ACT treatment, particularly in low-transmission 
areas where untreated gametocyte carriers maintain trans-
mission [36]. A  recent meta-analysis concluded that malaria 
control is limited by poor estimation of the gametocyte reser-
voir, with significant underestimates by light microscopy [37]. 
However, higher transmission risk has been demonstrated for 
microscopically patent infections [38]. Pre- and post-treatment 
microscopic gametocytemia were higher in both treatment 
arms here compared with a prior study at the same site [39] 
that used dihydroartemisinin-piperaquine as the blood-stage 
agent [1, 16] along with a higher 45-mg dose of primaquine 
(PQ). Though clinical data remain sparse, lower post-treatment 
100 000
A
AP (N = 103)
Treatment success (N = 135)
Pf recrudescence (N = 14)
Baseline IC50ASAP = 6.97
1829 940.1
Baseline IC50AP = 6.42
Baseline IC50treatmentsuccess= 6.97
Baseline IC50pf  recrudescence= 6.97




















































Figure 6. Atovaquone levels after drug administration. A, Atovaquone levels in nanomoles (nM) per milliliter (mL) of plasma in patients with uncomplicated malaria dosed 
with atovaquone-proguanil (AP) or artesunate-atovaquone-proguanil (ASAP) for 3 days. Horizontal lines represent mean parasite atovaquone 50% inhibitory concentration 
(IC50) values in nM at baseline for the respective treatment groups. Dashed horizontal lines represent mean parasite atovaquone IC50 values at baseline for the respective 
study groups. B, Atovaquone levels in patients who were cured (ACPR) and those who had a malaria recurrence. Horizontal lines represent mean parasite atovaquone IC50 
values in nM at baseline for the respective groups. C, Median day 7 drug levels of atovaquone for ACPR and recrudescent patients. One patient in the recrudescence group 
missed follow-up on day 7.
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gametocytemia seen in the ASAP arm was similar to previous 
findings in Thailand [13], suggesting added benefit of AS to 
eliminate sexual-stage parasites, and presumably reduce trans-
mission. Lack of a PQ control arm here limits conclusions 
regarding the efficacy of low-dose PQ to treat gametocytes. 
Despite this limitation, the data suggest both higher baseline 
microscopic gametocytemia and lower sexual-stage efficacy 
than previously observed at the Anlong Veng site. In a 2013 ran-
domized trial, pre-enrollment microscopic gametocytemia was 
roughly 10%, whereas the number carrying microscopically 
detectable gametocytemia at 1 week was significantly lower 
in those randomized to 45-mg single-dose PQ compared with 
untreated patients [16]. Evaluating potential drug–drug inter-
actions between AP and PQ as a possible cause of higher-than-
expected post-treatment gametocytemia may be useful.
Despite earlier in vitro and animal evidence, AP does not 
appear to have been an effective transmission-blocking agent 
on its own. High rates of microscopic gametocytemia despite 
single low-dose primaquine administration were seen here, 
with 30% still positive at day 3, suggesting increased malaria 
transmission risk [38]. Although concerning, the clinical sig-
nificance of apparently increased gametocytemia on trans-
mission of atovaquone-resistant malaria remains uncertain. 
Atovaquone-resistant P. berghei parasites were not transmis-
sible to mosquitoes in animal models [28] and had reduced 
P.f. gametocytemia in vitro [40]. Rapid in-host propagation
of Y268S cytb atovaquone resistance mutation has also been
attributed to mitochondrial heteroplasmy [29]. Heteroplasmy 
may lead to clinical resistance in the presence of lower IC50
values than previously proposed for clinical resistance
(29 nM) [28].
Implications for P. vivax Treatment and Malaria Elimination
High rates of post-treatment blood-stage P.v. were consistent 
with limited evidence of AP’s poor efficacy against blood-stage 
[28] and tissue-stage P.v. [41]. Concerns over rapid develop-
ment of blood-stage Pf resistance and cost have limited AP use
to high-risk areas in Southeast Asia. Mathematical modeling
suggests that it may be a poor option for elimination if used
alone [42]. Although AP remains a rational choice for rescue
therapy in Cambodia, its utility as a firstline agent outside areas
of severe multidrug resistance remains unclear. In a recent re-
port by the WHO, to delay resistance onset it was recommended 
that AP be tested in combination with ACTs [43]. Although
use of AP in combination with ACTs had been suggested as a
treatment for MDR P.f., it requires consideration of potential of
drug–drug interactions and evidence of improved efficacy [44].
There may also be implications for the use of AP as a chemopro-
phylaxis agent. However, these are less clear, as AP is thought
to act primarily in the liver on pre-erythrocytic parasite stages
(sometimes referred to as causal activity) [11]. To date, there
have been only limited reports of AP failures when used as
chemoprophylaxis. The recent approval of tafenoquine for both 
the radical cure of P. vivax and antimalarial chemoprophylaxis 
offers a compelling new alternative where screening for G6PD 
deficiency exists [45].
Study Limitations
Although there is an insufficient number of samples to 
make strong conclusions about mutation prevalence, the re-
sults provide useful information to develop a greater under-
standing of AP resistance in the setting of ART-R. In an area 
with no discernable atovaquone resistance mutations or other 
clear explanations for failure rates, AP efficacy is declining 
nonetheless. This finding is challenging to explain given near 
universal K13 C580Y ART-R mutations but negligible rates 
of cytochrome bc1 mutations conferring ATQ resistance. The 
population studied was overwhelmingly male. Although this 
may compromise the generalizability of results to women and 
children to some extent, malaria risk in Cambodia is largely 
occupational. With men making up the bulk of security and 
forestry workers in these at-risk professions, this may be an 
accurate representation of overall malaria risk. Another im-
portant limitation is an imbalance in sample size between KT 
and AV that proved unavoidable. AP efficacy was higher at 
the Kratie site, despite a lack of differences in bc1 mutations, 
though the study was not powered to detect site-specific dif-
ferences. Lower enrollment in Kratie limits definitive con-
clusions on both asexual- and sexual-stage efficacy by site. 
The sample size difference was governed as much by lo-
gistical as scientific considerations and is one of the chal-
lenges of executing clinical trials in austere settings. The AV 
site was well established before study inception, but several 
months were spent getting the KT site online after study in-
itiation. Establishing qualified sites capable of carrying out 
well-regulated clinical trials in remote areas is essential for 
conducting effective and informative clinical research in 
this region. Although definitive proof of different resist-
ance patterns between the two sites  cannot be established 
in the present study, important qualitative differences were 
observed, and the resistance patterns were not unexpected. 
From a statistical standpoint, the study was intended to de-
fine differences in effectiveness of the 2 regimens across both 
sites.
CONCLUSIONS
Given recent treatment failures, there’s been considerable 
debate on optimal treatment of MDR malaria in the region. 
Although not yet at “untreatable malaria,” optimizing use 
of available therapies and placing greater emphasis on 
nonpharmacologic approaches to malaria control should be 
employed in tandem [7]. Although clinical AP activity appears 
preserved in Eastern Cambodia, it is clearly under pressure 
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in Northwestern Cambodia, with cycloguanil resistance being 
a possible contributor. AP remains a reasonable rescue drug 
but cannot be recommended as a firstline agent in Cambodia. 
Co-administration of artesunate may reduce post-treatment 
gametocyte carriage, despite little added blood-stage effi-
cacy. Single low-dose primaquine administered with AP for 
this purpose appeared relatively ineffective compared with 
other blood-stage regimens [46] and higher doses of prima-
quine [16]. Given the findings, nonpharmacologic approaches 
to containing antimalarial resistance in Cambodia should be 
pursued.
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